Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

Rhea-AI Summary

Nexalin Technology (NASDAQ: NXL) will present an investor webinar on April 21, 2026 at 4:15 p.m. ET hosted by RedChip Companies. CEO Mark White will review Nexalin's non-invasive Deep Intracranial Frequency Stimulation (DIFS™) clinical evidence, Gen-3 HALO Clarity headset, Virtual Clinic platform, international regulatory clearances, and U.S. clinical and regulatory initiatives, followed by a live Q&A. Registration is free via RedChip.

Market Context

This announcement promotes Nexalin’s investor webinar highlighting its proprietary Deep Intracranial...

Analysis

This announcement promotes Nexalin’s investor webinar highlighting its proprietary Deep Intracranial Frequency Stimulation technology, Gen-3 HALO Clarity headset, and virtual clinic strategy for at-home treatment. Context from recent filings shows a 2024 operating loss of $7.8 million, negative operating cash flow of $3.94 million, and share count expansion to 13,303,523. Investors may watch for concrete commercialization milestones, updated clinical evidence, and capital needs discussed during the event.

Key Figures

Operating loss 2024: $7.8 million Operating cash flow 2024: $3.94 million Shares outstanding: 13,303,523 +5 more

8 metrics

Operating loss 2024 $7.8 million 2024 loss from operations (10-K/A)

Operating cash flow 2024 $3.94 million 2024 negative operating cash flow (10-K/A)

Shares outstanding 13,303,523 Post-raises share count, up from 7,436,562

Shares issued for cash 3,000,000 Shares issued to investors for cash

Equity raise proceeds $4.52 million Net proceeds from share issuance to investors

JV investment $96,000 Investment in joint venture (equity method)

Promissory note write-off $500,000 Defaulted promissory note principal written off

IPO warrant exercise price $4.15 Exercise price of expired IPO warrants (Form 8-K)

Key Terms

deep intracranial frequency stimulation, ai-enabled, regulatory clearances

3 terms

deep intracranial frequency stimulation medical

"non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology."

A medical technique that delivers patterned electrical pulses directly inside the skull to targeted brain areas, using implanted electrodes to change neural activity. Investors should care because outcomes, safety, and regulatory approval for devices and therapies using this approach can determine commercial viability, clinical adoption, and reimbursement — think of it as a precision electrical 'tune-up' for malfunctioning brain circuits that can create new markets or regulatory risks.

ai-enabled technical

"patented technology, real-time AI-enabled patient monitoring, and growing international footprint"

AI-enabled describes a product, service, or process that uses artificial intelligence—software that learns from data and makes decisions or predictions—as a core feature rather than a minor add-on. For investors it matters because AI-enabled offerings can boost productivity, lower costs or unlock new revenue streams; like adding a smart autopilot to a routine task, they can change a company's growth potential and competitive edge while also bringing higher upfront investment needs and distinct regulatory or ethical risks.

regulatory clearances regulatory

"With multiple international regulatory clearances in place and U.S. clinical and regulatory initiatives advancing"

Regulatory clearances are official approvals from government agencies that allow a medical product, device, drug or other regulated offering to be marketed or sold. Think of it like a safety inspection and license: it signals the product meets required safety and effectiveness standards, which can unlock revenue, reduce legal and market risk, and change a company’s growth timeline—information investors use to assess future sales and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).

The exclusive event will feature Nexalin’s CEO Mark White, who will provide an in-depth overview of the company’s differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin’s expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 HALO™ Clarity headset and integrated Virtual Clinic platform designed to enable scalable, physician-supervised, at-home treatment. With multiple international regulatory clearances in place and U.S. clinical and regulatory initiatives advancing, Nexalin is executing a clear pathway toward global commercialization. The presentation will also detail how Nexalin’s patented technology, real-time AI-enabled patient monitoring, and growing international footprint position the Company to capitalize on the rapidly expanding mental health and neurostimulation markets.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/NXL/87033006926

Questions can be pre-submitted to NXL@redchip.com or online during the live event.

About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.   

About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

Sign Up for RedChat
RedChat™ is an AI-powered investment research assistant designed to give investors instant access to critical insights from SEC filings, press releases, and corporate disclosures. Built to streamline small-cap and microcap stock research, RedChat analyzes thousands of public company documents and delivers clear, context-rich answers to investor questions in seconds. Instead of manually reviewing lengthy filings, investors can simply ask RedChat about financial results, partnerships, business strategy, or recent announcements and receive precise, source-based summaries. Investors can experience RedChat and start exploring stocks today at www.redchip.com/stocks or www.red.chat.

To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations.

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
NXL@redchip.com

FAQ

When is the Nexalin (NXL) investor webinar and how long will it run?

The webinar is scheduled for April 21, 2026 at 4:15 p.m. ET and is free to attend with a live Q&A. According to Nexalin, CEO Mark White will present company updates, clinical evidence, product progress, and take audience questions during the session.

What topics will Nexalin (NXL) cover during the April 21, 2026 investor webinar?

Nexalin will cover its DIFS™ technology, clinical evidence, product portfolio, and commercialization pathway. According to Nexalin, the presentation will include Gen-3 HALO Clarity headset details, the Virtual Clinic platform, international clearances, and U.S. clinical and regulatory initiatives.

How can investors register for the Nexalin (NXL) live investor webinar on April 21?

Investors can register for the free webinar via RedChip's registration page provided in the announcement. According to Nexalin, questions may be pre-submitted by email to NXL@redchip.com or submitted live during the webcast.

Will Nexalin (NXL) discuss regulatory progress and international clearances in the April 21 webinar?

Yes; regulatory progress and multiple international clearances will be discussed as part of the presentation. According to Nexalin, the company will outline U.S. clinical and regulatory initiatives and its pathway toward global commercialization.

Will Nexalin (NXL) present clinical evidence and institutional collaborations in the April 21 webinar?

Yes; Nexalin will highlight peer-reviewed studies and collaborations with institutions like UC San Diego during the presentation. According to Nexalin, the discussion will emphasize its expanding body of clinical evidence supporting DIFS™ technology.